Indication definition for Chronic Hand Eczema Development (CHE)
Chronic Hand Eczema development presents a small challenge, due to the fact that we generally observe reduced research activity in this indication. Hand eczema is an inflammation of the skin; the cause is often multi-factorial. Initial management includes avoiding causative irritants or allergens (e.g., by wearing impermeable gloves) and applying emollients and potent topical glucocorticoids.
(Published: PubMed, Tiltle: Hand eczema, Author: Coenraads PJ, Source: N Engl J Med. 2012;367(19):1829.)
Chronic Hand Eczema Development requires you to comprehensively analyze across the synonyms:
- chronic hand dermatitis (CHD)
- chronic hand eczema (CHE)
- hand dermatitis (HD)
- hand eczema
- severe hand eczema
- dyshidrotic eczema
Current treatment
In order to address your Chronic Hand Eczema Development effectively, the current treatment strategies have to be considered.
1st line treatment: Topical Corticosteroid
Topical corticosteroids are recommended as first line treatment in the management of HE, however continuous long-term treatment beyond 6 weeks only when necessary and under careful medical supervision.
For patients with the severe Chronic Hand Eczema a second line treatment, applying a systemic approach, relative to topical corticosteroids may be required.
2nd line treatment
- Alitretinoin, an endogenous retinoid related to vitamin A. Studies have shown that oral alitretinoin is effective and well tolerated in the treatment of severe chronic hand eczema.
- Cyclosporine, a cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed, introduced 1992).
Selected current research
- Delgocitinib, a janus kinase (JAK) inhibitor, is being developed by Japan Tobacco for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.
- Asana Biosciences develops an oral janus kinase/SYK inhibitor suppressing inflammation and improves epidermal barrier markers in patients with systemic dermatitis.
Considering your compound for Chronic Hand Eczema development?
Please ask for a Reference Clinical Development Plan (CDP) or contact us under referencecdp.com.
Reference CDP gives you a head start into your Clinical Development.
intilaris LifeSciences helps you to Plan, Design, and Execute efficient clinical projects.
